130 related articles for article (PubMed ID: 36977512)
1. De novo monocytic-M5b AML with t(8;16) (p11.2; p13.3) KAT6A/CREBBP fusion and FLT3-TKD mutation complicated by chemotherapy-induced Takotsubo cardiomyopathy.
Ananthaneni A; Benzar T; Hafiz N; Akabane H
BMJ Case Rep; 2023 Mar; 16(3):. PubMed ID: 36977512
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
Xie W; Hu S; Xu J; Chen Z; Medeiros LJ; Tang G
Ann Hematol; 2019 May; 98(5):1149-1157. PubMed ID: 30759270
[TBL] [Abstract][Full Text] [Related]
3. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype.
Barrett R; Morash B; Roback D; Pambrun C; Marfleet L; Ketterling RP; Harrison K; Berman JN
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28097792
[TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia with t(8;16)(p11.2;p13.3)/ KAT6A-CREBBP in a Patient with an NF1 Germline Mutation and Clinical Presentation Mimicking Acute Promyelocytic Leukemia.
Donnelly L; Rankins C; Bruno XJ; McKinnon W; Devitt K; Gardner JA
J Assoc Genet Technol; 2020; 46(3):135-139. PubMed ID: 32889804
[TBL] [Abstract][Full Text] [Related]
5. Distinctive Flow Cytometric and Mutational Profile of Acute Myeloid Leukemia With t(8;16)(p11;p13) Translocation.
Aqil B; Gao J; Stalling M; Sukhanova M; Duncavage EJ; Lu X; Wolniak KL; Kreisel F; Yaseen NR
Am J Clin Pathol; 2022 May; 157(5):701-708. PubMed ID: 34698340
[TBL] [Abstract][Full Text] [Related]
6. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression.
Camós M; Esteve J; Jares P; Colomer D; Rozman M; Villamor N; Costa D; Carrió A; Nomdedéu J; Montserrat E; Campo E
Cancer Res; 2006 Jul; 66(14):6947-54. PubMed ID: 16849538
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of PML-RARA gene fusion, chromosome 8 trisomy, and FLT3 ITD mutation in a young female patient with de novo acute myeloid leukemia and early death: A CARE case report.
Tripon F; Crauciuc GA; Bogliş A; Moldovan V; Sándor-Kéri J; Benedek IJ; Trifa AP; Bănescu C
Medicine (Baltimore); 2020 Apr; 99(14):e19730. PubMed ID: 32243411
[TBL] [Abstract][Full Text] [Related]
9. t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia.
Wong KF; Yuen HL; Siu LL; Pang A; Kwong YL
Hum Pathol; 2008 Nov; 39(11):1702-7. PubMed ID: 18657848
[TBL] [Abstract][Full Text] [Related]
10. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A; Taki T; Koga D; Tabuchi K; Tawa A; Hanada R; Tsuchida M; Horibe K; Tsukimoto I; Adachi S; Kojima S; Hayashi Y
Int J Hematol; 2012 Oct; 96(4):469-76. PubMed ID: 22915059
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Santos FP; Jones D; Qiao W; Cortes JE; Ravandi F; Estey EE; Verma D; Kantarjian H; Borthakur G
Cancer; 2011 May; 117(10):2145-55. PubMed ID: 21523727
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a
Panagopoulos I; Andersen K; Ramslien LF; Ikonomou IM; Micci F; Heim S
Anticancer Res; 2021 Apr; 41(4):1753-1760. PubMed ID: 33813379
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract][Full Text] [Related]
14. Comparison between karyotyping-FISH-reverse transcription PCR and RNA-sequencing-fusion gene identification programs in the detection of KAT6A-CREBBP in acute myeloid leukemia.
Panagopoulos I; Torkildsen S; Gorunova L; Tierens A; Tjønnfjord GE; Heim S
PLoS One; 2014; 9(5):e96570. PubMed ID: 24798186
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Kayser S; Hills RK; Langova R; Kramer M; Guijarro F; Sustkova Z; Estey EH; Shaw CM; Ráčil Z; Mayer J; Zak P; Baer MR; Brunner AM; Szotkowski T; Cetkovsky P; Grimwade D; Walter RB; Burnett AK; Ho AD; Ehninger G; Müller-Tidow C; Platzbecker U; Thiede C; Röllig C; Schulz A; Warsow G; Brors B; Esteve J; Russell NH; Schlenk RF; Levis MJ
Br J Haematol; 2021 Mar; 192(5):832-842. PubMed ID: 33529373
[TBL] [Abstract][Full Text] [Related]
16. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.
Coenen EA; Zwaan CM; Reinhardt D; Harrison CJ; Haas OA; de Haas V; Mihál V; De Moerloose B; Jeison M; Rubnitz JE; Tomizawa D; Johnston D; Alonzo TA; Hasle H; Auvrignon A; Dworzak M; Pession A; van der Velden VH; Swansbury J; Wong KF; Terui K; Savasan S; Winstanley M; Vaitkeviciene G; Zimmermann M; Pieters R; van den Heuvel-Eibrink MM
Blood; 2013 Oct; 122(15):2704-13. PubMed ID: 23974201
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Bacher U; Haferlach C; Kern W; Haferlach T; Schnittger S
Blood; 2008 Mar; 111(5):2527-37. PubMed ID: 17965322
[TBL] [Abstract][Full Text] [Related]
18. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.
Sakaguchi M; Yamaguchi H; Kuboyama M; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Date K; Nakajima N; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
Int J Hematol; 2019 Nov; 110(5):566-574. PubMed ID: 31432396
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
20. Morphological, cytogenetic and molecular characterisation of FLT3 mutations in Pakistani patients with de novo acute myeloid leukaemia: A single centre experience.
Faiz M; Rashid F
Malays J Pathol; 2023 Aug; 45(2):205-214. PubMed ID: 37658530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
